C117P: Emicizumab Biosimilar, Human F10, F9 Monoclonal Antibody

Catalog No.: C117P | **Product Name:** Emicizumab Biosimilar, Human F10, F9 Monoclonal Antibody

The research grade Emicizumab biosimilar protein is for research use only (RUO). Recombinant human IgG4 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.

PRODUCT SPECIFICATIONS

Catalog No.	C117P
Product Name	Emicizumab Biosimilar, Human F10, F9 Monoclonal Antibody
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	Emicizumab; ACE-910; RG6013; hBS910; F10, F9
Summary	Recombinant Humanized Bispecific IgG4 kappa Monoclonal Antibody.
Isotype	Human IgG4 kappa.
Source/Host	The anti-human F10, F9 monoclonal antibody emicizumab biosimilar was produced in mammalian cells.
Specificity/Sensitivity	The in vivo grade emicizumab biosimilar specifically binds to the F10, F9 protein.
Applications	ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by emicizumab.
Form Of Antibody	0.2 μM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin	< 1 EU per 1 mg of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	The Emicizumab Biosimilar, Human F10, F9 Monoclonal Antibody is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Note	The research grade Emicizumab biosimilar protein is for research use only (RUO). Recombinant human IgG4 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.

REFERENCES & BACKGROUND

What is emicizumab biosimilar research grade? Emicizumab (trade name Hemlibra) is a humanized bispecific IgG4 monoclonal antibody that bridges activated factor IX (FIXa) and factor X (FX), thereby restoring the function of missing activated factor VIII in patients with hemophilia A. By mimicking the cofactor function of factor VIII, emicizumab enables effective hemostasis. Emicizumab is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors. Emicizumab biosimilar uses the same protein sequences as the therapeutic antibody emicizumab.